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In Brief
The TGF-b pathway uses transcriptional
regulation through SMAD transcription
factors to modulate cell-context-specific
phenotypes. Tufegdzic Vidakovic et al.
show that in breast-tumor-initiating cells
(BTICs), type-specific DNA and histone
modifications help determine whether the
response to TGF-b is pro-oncogenic or
tumor suppressive. These landscapes act
both in synergy and independently of cell-
type-specific SMAD3 binding to TGF-b
target genes to modulate context-specific
transcriptional regulation by TGF-b/
SMAD3.
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The transforming growth factor beta (TGF-b)
signaling pathway exerts opposing effects on cancer
cells, acting as either a tumor promoter or a tumor
suppressor. Here, we show that these opposing
effects are a result of the synergy between SMAD3,
a downstream effector of TGF-b signaling, and the
distinct epigenomes of breast-tumor-initiating cells
(BTICs). These effects of TGF-b are associated with
distinct gene expression programs, but genomic
SMAD3 binding patterns are highly similar in the
BTIC-promoting and BTIC-suppressing contexts.
Our data show cell-type-specific patterns of DNA
and histone modifications provide a modulatory
layer by determining accessibility of genes to regula-
tion by TGF-b/SMAD3. LBH, one such context-spe-
cific target gene, is regulated according to its DNA
methylation status and is crucial for TGF-b-depen-
dent promotion of BTICs. Overall, these results
reveal that the epigenome plays a central and previ-
ously overlooked role in shaping the context-specific
effects of TGF-b in cancer.
INTRODUCTION
The effects of transforming growth factor beta (TGF-b) in tissue
homeostasis depend heavily on cellular context (Massague´,
2012). TGF-b has been shown to both induce proliferation and
suppress cell growth, stimulate stem cell self-renewal and pro-
mote differentiation, and inhibit early and promote late malignant
transformation (Gomis et al., 2006; Guasch et al., 2007; Mas-
sague´, 2008, 2012).
In breast cancer, TGF-b can either promote or inhibit tumor-
initiating cells (breast TICs, or BTICs), which are responsible
for cancer initiation, propagation, and metastasis (Bierie and
Moses, 2009; Bruna et al., 2012; Mani et al., 2008; Scheel
et al., 2011). We have previously shown these opposing effects
of TGF-b depend on breast cancer subtype (Bruna et al.,
2012). BTICs are activated only in Claudinlow breast cancer,
while in all other subtypes, TGF-b inhibits BTICs. Since no muta-2480 Cell Reports 13, 2480–2490, December 22, 2015 ª2015 The Autions in TGF-b pathway genes have been associated with spe-
cific breast cancer subtypes (Cancer Genome Atlas Network,
2012), the underlying mechanism of this dichotomy is unlikely
to be genetic.
TGF-b signaling is initiated by binding of TGF-b to its cognate
receptor, TGFBR II, resulting in phosphorylation of the transcrip-
tion factors SMAD2 and SMAD3 (Massague´ et al., 2005). Upon
phosphorylation, SMAD2 and SMAD3 associate with SMAD4
and translocate to the nucleus, where they partner up with
additional transcription factors (TFs) to regulate target gene
expression (Massague´ et al., 2005). Remarkably, TGF-b univer-
sally relies on SMADs despite regulating cell-type-specific tran-
scriptional programs (Massague´, 2012). The current model is
that cell-type-specific partner TFs guide SMADs to distinct
genes, thus resulting in context-specific gene regulation and
specific biological effects of TGF-b (Massague´, 2012; Mullen
et al., 2011; Xu et al., 2015).
Here, we mapped genome-wide SMAD3 binding patterns in
BTICs that model the opposing effects of TGF-b (Bruna et al.,
2012). This showed that differential SMAD3 binding does not
fully account for context-specific TGF-b target gene regulation,
and further experiments revealed that distinct epigenetic states
are responsible. We identify transcription factor LBH as a proto-
typical TGF-b target gene regulated by differential DNA methyl-
ation and show it is essential for the BTIC-promoting activity of
TGF-b. Taken together, these data reveal an important role for
epigenetic determinants in regulation of the context-specific
actions of TGF-b in cancer.
RESULTS
SMAD3 Binding to Gene-Proximal Regions Mediates
TGF-b-Dependent Gene Expression in BTICs
Two cell lines that we previously showed represent the
opposing effects of TGF-b (Bruna et al., 2012) were used as
BTIC model systems in all experiments: MDA-MB-231 for
BTIC promoting, and HCC-1954 for BTIC suppressing (Fig-
ure 1A). Cells were grown in suspension as mammosphere cul-
tures to enrich for BTICs (Bruna et al., 2012; Dontu et al., 2003a,
2003b). Confirming our previous data (Bruna et al., 2012), the
canonical TGF-b signaling cascade is intact and similarly acti-
vated by its ligand in both models, as shown by SMAD2 phos-
phorylation (Figure 1B).thors
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Figure 1. SMAD3 Mediates Both the
BTIC-Promoting and BTIC-Suppressing
Programs of TGF-b
(A) MDA-MB-231 and HCC-1954 first generation
mammosphere cultures with and without addition
of TGF-b. TGF-b was added to the media at the
moment of cell seeding and mammospheres were
allowed to form for 7 days. Note that this is not a
quantitative assay.
(B) Western blot showing SMAD2 phosphorylation
levels upon TGF-b pathway induction. 7-day-old
mammospheres were treated with exogenous
TGF-b ligand for 1 hr. Total SMAD2/3 and b-actin
levels were used as loading controls.
(C) Comparison of TGF-b-dependent genes in
MDA-MB-231 and HCC-1954 BTICs. MDA-MB-
231 and HCC-1954 cells were grown as mam-
mospheres for 7 days and treated with TGF-b
for 1, 3, 6, and 24 hr, and gene expression profiling
was performed using Illumina HumanHT-12
BeadChips. The plot shows the number of TGF-
b-dependent genes in each BTIC at each time
point (false discovery rate [FDR] < 0.1; data pre-
sented on the log2 scale to show both the early and
late response). TGF-b-dependent genes unique to
MDA-MB-231 or HCC-1954 BTICs are labeled in
red and blue, respectively, whereas genes regu-
lated by TGF-b in both BTIC types are labeled in
gray. The number of genes within each category is
indicated within bars. Also see Table S1.
(D) Annotation of SMAD3 binding sites in the
genomes of MDA-MB-231 BTICs (red) and HCC-
1954 BTICs (blue). ChIP-seq was performed on
7-day-old mammospheres treated with TGF-b for
3 hr. See Supplemental Experimental Procedures
for details.
(E) Heatmaps showing gene expression dynamics
upon TGF-b stimulation in each BTIC indepen-
dently. Bar plots below each gene expression time point show the proportion of TGF-b-dependent genes at that particular time point that were detected as bound
by SMAD3 in the ChIP-seq experiment (bar below the 1-hr time point in HCC-1954 is absent as zero genes were detected as significantly differentially expressed).
Asterisks indicate statistical significance, which was determined with the chi-square test, using TGF-b-independent gene sets as background (refer to Sup-
plemental Experimental Procedures for details).The transcriptional responses associated with the opposing
effects of TGF-b on BTICs were characterized by gene expres-
sion profiling. BTIC-enriched mammosphere cultures (hereafter
referred to as ‘‘BTICs’’) were treated with TGF-b for varying
amounts of time (1, 3, 6, and 24 hr) to capture both early
and late transcriptional responses. Comparing the lists of
TGF-b-dependent genes revealed that only a small fraction
is commonly regulated in both BTIC types (‘‘shared’’ genes)
(Figure 1C; Table S1). The vast majority of genes displayed
cell-context-specific regulation, indicating that distinct and
non-overlapping TGF-b-dependent transcriptional regulation
occurs in BTICs with opposing (pro-oncogenic and tumor-sup-
pressive) responses.
We previously showed that the BTIC-promoting and BTIC-
suppressing effects of TGF-b depend on SMADs (Bruna
et al., 2012). Hence, we hypothesized that SMADs mediate the
TGF-b-dependent transcriptional regulation in both contexts.
SMAD3 binding patterns in BTICs were mapped genome-wide
after 3 hr of TGF-b exposure using chromatin immunoprecipita-
tion and sequencing (ChIP-seq). We chose the 3-hr time point asCell Repit was the earliest at which significant TGF-b-dependent gene
expression changes were detected in both models. Genomic
annotation of SMAD3 binding sites showed a significant fraction
of peaks (>30%) is directly associated with genes, with the
remainder being at distal regulatory regions (Figure 1D).
We defined gene-proximal SMAD3 binding when peaks
occurred within a genomic unit encompassing the 1,500 bp
upstream of the transcription start site (TSS) to the end of the
gene body. Comparing TGF-b-dependent and TGF-b-indepen-
dent (background) gene sets revealed that both early- and
late-responder genes are strongly enriched for gene-proximal
SMAD3 binding in both BTIC types (Figure 1E). These data
suggest that gene-proximal SMAD3 binding mediates TGF-
b-dependent gene regulation in both contexts.
Differential SMAD3 Binding Is Not the Sole Determinant
of Context-Specific Gene Regulation by TGF-b
The prevailing model for TGF-b context-dependent transcrip-
tional regulation assumes binding of SMAD3 to different genes
in different cell types (Massague´, 2012; Mullen et al., 2011).orts 13, 2480–2490, December 22, 2015 ª2015 The Authors 2481
Our data showed instead that a substantial proportion of SMAD3
binding sites are identical in both BTIC types (50% in MDA-MB-
231 and 37% in HCC-1954) (Figure 2A). Motif analysis identified
a number of distinct DNAmotifs under SMAD3 binding sites (Fig-
ures S1A and S1C), including ‘‘canonical’’ SMAD consensusmo-
tifs (Figures S1D and S1E) (Dennler et al., 1998; Jonk et al., 1998;
Koinuma et al., 2009; Shi et al., 1998; Zawel et al., 1998). Thema-
jority of identified motifs also corresponded to known SMAD
binding partners (Figure S1B), which have been implicated in
TGF-b responses by single gene studies (Gomis et al., 2006; Koi-
numa et al., 2009; Liberati et al., 1999;Massague´, 2012; Sundqv-
ist et al., 2013; Xu et al., 2015; Zaidi et al., 2002). These results
indicate that SMAD3 associates with diverse co-factors that
guide it to both shared and cell-type-specific genomic locations
in BTICs.
Inspection of ChIP-seq profiles around BTIC context-specific
TGF-b-dependent genes revealed that SMAD3 binding is not
necessarily associated with the regulation of the underlying
gene, but rather can adopt four different binding modes (Fig-
ure 2B). For example, a gene regulated by TGF-b only in MDA-
MB-231 BTICs (MDA-unique gene) can be: (1) uniquely bound
by SMAD3 in MDA-MB-231 (binding mode 1), (2) uniquely bound
bySMAD3 inHCC-1954 (bindingmode2), (3) commonlyboundby
SMAD3 in both cell types (binding mode 3), and (4) not bound by
SMAD3 in either cell type (binding mode 4). The same applies to
the TGF-b-dependent genes regulated uniquely in HCC-1954
BTICs (HCC-unique genes) (Figure 2B, bottom panels). These re-
sults differ from those previously reported using non-malignant
cellular models, where TGF-b’s cell-context-specific genes are
almost exclusively associated with cell-type-specific SMAD3
binding patterns (Mullen et al., 2011).
We systematically investigated how these four SMAD3
binding modes contribute to gene regulation downstream of
TGF-b. We found that TGF-b-dependent early-responder genes
(derived 6 hr post-TGF-b treatment) are highly enriched for the
common SMAD3 binding mode (mode 3) in both MDA-MB-231
and HCC-1954 BTICs (Figure 2C, upper table). TGF-b-depen-
dent late-responder genes (derived 24 hr post-TGF-b treatment)
show enrichment of both common (mode 3) and cell-type-
unique SMAD3 binding (modes 1 and 2; Figure 2C, lower table).
Notably, these BTIC type-unique SMAD3 binding events are
associated with TGF-b-dependent genes in the corresponding
model (MDA-unique genes with MDA-unique SMAD3 binding,
and HCC-unique genes with HCC-unique SMAD3 binding)
24 hr after pathway activation. Genes not bound by SMAD3 in
either cell type (mode 4) are relatively depleted in both the early
and late TGF-b-responder genes, as could be expected based
on the results presented in Figure 1E.
Based on the observed enrichment of the common SMAD3
binding mode in all gene groups and particularly in the early
TGF-b responders, we conclude that cell-type-specific gene-
proximal SMAD3 binding is not the sole determinant of
context-specific TGF-b transcriptional responses.
In embryonic stem cells and muscle and lymphocyte progen-
itors, SMAD3 occupies distinct, non-overlapping sites within the
gene, even when binding to the same gene (Mullen et al., 2011).
To test if this also occurs in BTICs, we systematically categorized
SMAD3 binding events into three classes: (1) uniquely present in2482 Cell Reports 13, 2480–2490, December 22, 2015 ª2015 The AuMDA-MB-231 (Figure 2D, red peak), (2) uniquely present in HCC-
1954 (Figure 2D, blue peak), and (3) present in identical position
in both cell types (Figure 2D, gray peaks). For each context-spe-
cific TGF-b-dependent gene, we derived a composite SMAD3
binding profile (Figure 2D, right). This analysis revealed that
only a small fraction of commonly bound genes (mode 3)
possess mutually exclusive SMAD3 binding patterns (Figures
2E and 2F, light blue boxes). In fact, most genes that are
commonly bound by SMAD3 (mode 3) display either a mixed
occupancy profile, where both identical and cell-type-specific
binding sites are present, or an identical occupancy profile,
where SMAD3 binds at identical coordinates within a given
gene in both cell types (Figures 2E and 2F). These findings led
us to hypothesize that for many genes (at least 422 MDA-unique
genes and 264 HCC-unique genes) possessing remarkably
similar SMAD3 binding patterns in BTICs (yellow boxes, Figures
2E and 2F), other regulatory determinants might govern the
context-specific transcriptional outputs of TGF-b.
We obtained similar results for SMAD3 binding events located
distally to genes (Figures S2A–S2F; Supplemental Experimental
Procedures); however, for simplicity, these are not presented in
the Results section.
Context-Specific Epigenetic Landscape Modulates
TGF-b/SMAD3-Dependent Transcriptional Regulation
In breast cancer, epigenetic modifications have characteristic,
subtype-specific genomic patterns (Bediaga et al., 2010; Holm
et al., 2010). We therefore reasoned that cell-type-specific
epigenetic landscapes in BTICs could contribute to shaping
the TGF-b transcriptional responses. We profiled the chromatin
configuration in BTICs by mapping RNA polymerase II (Pol II)
binding, histone H3 lysine 27 acetylation (H3K27ac), histone
H3 lysine 4 trimethylation (H3K4me3), and histone H3 lysine 27
trimethylation (H3K27me3) using ChIP-seq. We also mapped
CpG DNA methylation using methyl-binding domain pull-down
and sequencing (MBD-seq). These epigenetic marks were pro-
filed in untreated BTIC cultures to determine whether the
‘‘native’’ chromatin configuration existing prior to TGF-b stimula-
tion was what modulated the context-specific transcriptional
response.
Peak-based analysis showed the genomic distribution of
the epigenetic marks occurred in the expected patterns: Pol II
peaks localized predominantly to enhancer and promoter re-
gions, H3K4me3 peaks to promoter regions, H3K27ac peaks
to enhancer and promoter regions, H3K27me3 peaks to inter-
genic domains, and DNA methylation peaks to gene-proximal
elements (Figure S3A). Comparative analysis revealed that
MDA-MB-231 and HCC-1954 BTICs harbor distinct epigenetic
landscapes (Figure S3B).
Overlaying the epigenetic marks with SMAD3 binding data
showed that SMAD3 binds to open chromatin (marked by
H3K27ac, Pol II, and H3K4me3) and not to closed chromatin
(marked by H3K27me3 and DNA methylation) (Figure S3C).
Additionally, BTIC type-specific SMAD3 binding coincided
with the type-specific patterns of Pol II and H3K27ac (Fig-
ure S3D). This suggested that the pre-existing cell-type-spe-
cific chromatin context determines where SMAD3 binds upon
TGF-b stimulation.thors
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Figure 2. Differential SMAD3 Binding Is Not the Sole Determinant of Context-Specific Gene Regulation by TGF-b
(A) Occupancy plots showing SMAD3 binding sites in MDA-MB-231 (red) and HCC-1954 (blue) BTICs relative to each other, within the 5-kb window around the
peak summits. Also see Figure S1.
(B) Gene tracks showing binding of SMAD3 in MDA-MB-231 (red) and HCC-1954 (blue) BTICs, at genes regulated by TGF-b only in MDA-MB-231 (top) and HCC-
1954 (bottom) BTICs. SMAD3 adopts four modes of occupancy at these genes: bound in a cell-context-specific manner (modes 1 and 2), bound commonly in
both BTIC types (mode 3), or not bound in either (mode 4).
(C) Genome-wide analysis showing the enrichment of each of the four SMAD3 binding modes (from B) at TGF-b-dependent genes. Gene expression data from
6-hr and 24-hr time points were used. Enrichment was calculated over SMAD3 binding distribution in the TGF-b-independent, background gene set (see
(legend continued on next page)
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We next asked whether the pre-existing BTIC type-spe-
cific gene-proximal chromatin patterns prime genes for TGF-
b-mediated regulation. To address this question, we combined
differential binding analysis with gene set enrichment analysis
(Figure 3A). This revealed that context-specific TGF-b-depen-
dent genes are enriched for those with cell-type-specific epige-
netic patterns, characterized by higher levels of gene-proximal
open chromatin marks (H3K4me3, H3K27ac, and Pol II) (Fig-
ures 3B and 3C) and lower levels of repressive chromatin
marks in the corresponding BTIC type (Figure S3E; HCC-unique
genes depleted from H3K27me3; MDA-unique genes depleted
from DNA methylation). We also noted that TGF-b-dependent
genes unique to MDA-MB-231 showed higher levels of DNA
methylation in HCC-1954 (Figure 3B). Together, these results
show that distinct epigenetic landscapes in BTICs modulate
context-specific responses to TGF-b: high levels of H3K4me3,
H3K27ac, and Pol II in gene-proximal space permit, while TSS
DNA methylation and H3K27me3 impede, TGF-b/SMAD3-
dependent regulation of gene expression.
We next asked whether these epigenetic differences in the
gene-proximal space act in synergy with, or independently of,
differential SMAD3 binding to control context-specific TGF-b
target gene regulation. For this purpose, genes with differential
levels of SMAD3 were defined using the same analysis as for
the chromatin factors (Figure 3A). This enabled us to stringently
detect genes with the most pronounced differences in SMAD3
binding intensity between BTICs. For each TGF-b context-spe-
cific gene group (MDA unique and HCC unique), we derived
three sets of signatures: SMAD3-high gene set (genes that
display higher levels of SMAD3 in the corresponding BTIC
type), open chromatin-high gene set (genes with higher levels
of either H3K4me3, H3K27ac or Pol II in the corresponding
BTIC type), and DNA hypo-methylation gene set (genes with
lower levels of TSS DNA methylation in the corresponding
BTIC type) (Table S2). Comparison of these gene sets in each
BTIC type revealed that virtually all genes within the SMAD3-
high set (58 in MDA and 30 in HCC) also belong to the open chro-
matin-high gene set (Figures 3D and 3E). This shows that in order
to achieve type-specific gene regulation, differential binding of
SMAD3 is assisted by gene-proximal open chromatin configura-
tion, as shown for IGDCC4 and GRAMD2 (epigenome-assisted
TGF-b-regulated genes; Figures 4A and 4B). Moreover, a sub-
stantial number of TGF-b-dependent genes in each BTIC type
(401 MDA-unique genes; 181 HCC-unique genes) belonged to
the open chromatin-high and/or DNA hypo-methylation sets,
but not to the SMAD3-high set. Hence, the context-specific
TGF-b-dependent regulation of the genes in this set is likely to
be mediated by epigenetic differences (epigenome-directedSupplemental Experimental Procedures for details). Note that the common binding
but on different sites in the two BTICs. Also see Figure S2.
(D) Schematic of the gene-based SMAD3 binding analysis. For each gene in the g
shared binding sites (gray) were calculated and represented as a composite pro
(E and F) Gene-based SMAD3 binding analysis on context-specific TGFb-depen
TGF-b stimulation were used. Genes are aligned along the x axis and grouped into
modes are indicated below the plot in gray. Gene examples are highlighted with
binding patterns, and the yellow box marks those with predominantly similar o
Supplemental Experimental Procedures for details.
2484 Cell Reports 13, 2480–2490, December 22, 2015 ª2015 The AuTGF-b-regulated genes), as highlighted by ADAM8 and IGFBP5
(Figures 4A and 4B). This analysis also revealed that only a
subset of SMAD3-high genes overlap with the DNA hypo-meth-
ylated set, suggesting that differential DNA methylation and dif-
ferential SMAD3 binding appear to independently contribute to
context-specific gene regulation by TGF-b.
Taken together, these results suggest that cell context-spe-
cific transcriptional responses to TGF-b are mediated by both
SMAD3 and the epigenome. The epigenomic landscape primes
genes for transcriptional regulation by TGF-b signaling, both in
synergy with, and independently of, differential SMAD3 binding.
Differential DNA Methylation of LBH Impacts the BTIC-
Promoting Effects of TGF-b
To functionally validate the impact of the epigenome on the
opposing effects of TGF-b on BTICs, we focused on context-
specific TGF-b-dependent genes with differential DNA methyl-
ation. Interesting links have been proposed between normal
developmental processes and breast cancer (Holm et al.,
2010; Prat et al., 2010), and therefore, we selected two genes
encoding developmental TFs for further analysis: Limb Bud
and Heart Development (LBH), and Vestigial-like family member
3 (VGLL3).
LBH and VGLL3 are induced by TGF-b in a SMAD2/3 depen-
dent manner in BTICs from MDA-MB-231, but not in HCC-1954
(Figures S4A–S4D). LBH is bound by SMAD3, and Pol II at an
identical intragenic regulatory region in both cell types (Fig-
ure 5A), but in HCC-1954, the TSS-proximal region is DNA
methylated (coinciding with lack of Pol II binding) (Figure 5A).
This suggests that context-specific regulation of LBH, despite
remarkably similar SMAD3 binding, is dependent on the methyl-
ation status of its promoter (epigenome directed). In contrast,
VGLL3 is bound by SMAD3 and Pol II only in MDA-MB-231
BTICs, while its TSS harbors DNA methylation only in HCC-
1954 (Figure 5B). Hence, TGF-b-dependent regulation of
VGLL3 is epigenome assisted.
To test if promoter methylation of LBH and VGLL3 determines
their context-specific TGF-b-dependent transcriptional regula-
tion, BTICs were treated with 5-aza-20-deoxycytidine (5-aza-
dC) prior to TGF-b stimulation, which resulted in reduction of
overall methylation levels at these loci in HCC-1954 (Figures
S4F and S4G). In HCC-1954, 5-aza-dC treatment reactivated
both LBH and VGLL3 expression, and TGF-b treatment further
induced LBH, but not VGLL3 (Figures 5C, 5D, and S4E). This
shows that promoter DNA methylation is sufficient to block
TGF-b/SMAD3-mediated induction of LBH. Erasure of DNA
methylation from VGLL3 failed to restore its TGF-b-dependent
induction in HCC-1954, as predicted due to the absence ofmode (3) does not exclude SMAD3 binding sites that occur on the same genes
enome, the number of context-specific SMAD3 binding sites (red and blue) and
file.
dent genes (performed as outlined in D). TGF-b-dependent genes 24 hr post-
distinct categories based on their SMAD3 composite profiles. SMAD3 binding
dashed lines. The light blue box marks genes with mutually exclusive SMAD3
r identical SMAD3 binding patterns in both BTICs. Also see Figure S2. See
thors
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Figure 3. Epigenetic Wiring Confers Predis-
position for Context-Specific TGF-b Re-
sponses
(A) Schematic of the analysis approach. Differences
between BTICs in the levels of each factor were
defined based on differential binding analysis within
the gene-proximal space (1,500 bp upstream of the
TSS to gene end), apart from DNA methylation, for
which only TSS-proximal regions were considered
(1,500 bp to +1,500 bp around the TSS). Gene set
enrichment analysis was then conducted, testing
the enrichment of differentially bound gene sets
within the context-specific TGF-b-dependent gene
sets (MDA-unique andHCC-unique genes). Refer to
Supplemental Experimental Procedures for details.
(B and C) Over-representation of genes with cell-
type-specific levels of epigenetic modifications and
Pol II, within the context-specific TGF-b-dependent
genes (MDA-unique on the left and HCC-unique on
the right). The significance of enrichment is repre-
sented as a p value on a bi-symmetrical x axis. The
left and the right sides of the axis correspond to the
enrichment of genes with more binding of the cor-
responding mark in HCC-1954 (blue) and MDA-
MB-231 (red), respectively. p value cutoffs were set
at 0.05 (log10(1.33) = 0.05) (dashed lines). TGF-
b-dependent genes derived at the 24-hr time point
were used (see Supplemental Experimental Pro-
cedures for details). Also see Figure S3.
(D and E) Comparison of SMAD3-high, open
chromatin-high, and DNA hypo-methylation gene
sets within the MDA-unique and HCC-unique TGF-
b-dependent genes (24-hr gene expression time
point). For each BTIC, SMAD3-high, open chro-
matin-high, and DNA hypo-methylation gene sets
were defined as groups of genes with differentially
higher SMAD3 levels, differentially higher open
chromatin levels, and differentially lower DNA
methylation levels when compared to the opposing
BTIC type (differential binding analysis performed
as in A). Also see Table S2.SMAD3 binding at this locus. Taken together, these results
confirm that the epigenetic configuration not only determines
baseline gene expression levels, but it also controls TGF-b/
SMAD3-dependent transcriptional regulation.
To assess the functional implications of epigenome-directed
and epigenome-assisted mechanisms, we investigated whether
LBH and VGLL3 are required for the effects of TGF-b on BTICs.
We knocked down their expression using short interfering RNAs
(siRNAs), resulting in 80%and 50% reduction of LBH and VGLL3
transcript levels, respectively (Figures S5A and S5B). Mammo-
sphere-initiating cell (MS-IC) and colony-forming cell (CFC)
assays were used to test self-renewal and proliferation of BTICs
(Bruna et al., 2012; Dontu et al., 2003a, 2003b).
LBH knockdown in untreated cells reduced BTIC self-renewal
and proliferation in both cell lines (Figures 6A and 6B), suggest-
ing that LBH is required for baseline BTIC maintenance re-
gardless of the response to TGF-b. In HCC-1954 BTICs, LBH
transcripts are expressed at very low levels despite promoter
methylation, and their reduction by siRNA treatment (Figure S5A)
results in measurable effects in the BTIC assays (Figures 6A and
6B). These LBH transcripts are likely to originate from low levelsCell Repof transcription initiated at methylated DNA molecules with
variegated CpG methylation patterns (‘‘epipolymorphisms’’;
Landan et al., 2012), as determined by reduced representation
bisulfite sequencing (RRBS) (Figure 6C). Thus, residual tran-
scription initiated at epipolymorphic promoters can be function-
ally important.
In MDA-MB-231, LBH depletion impaired the BTIC-promoting
effects of TGF-b by more than 2-fold (Figures 6A and 6B). In
contrast, in HCC-1954, LBH depletion did not affect BTIC sup-
pression by TGF-b (Figures 6A and 6B). In both cells lines,
VGLL3 depletion had no effect on BTICs after TGF-b treatment
(Figures 6A and 6B). Altogether, these results suggest that epi-
genome-directed gene co-regulation with SMAD3, as occurs
with LBH, acts as amolecular switch that mediates the opposing
effects of TGF-b on BTICs.
We previously showed that TGF-b specifically promotes BTIC
activity only in Claudinlow cell lines (Bruna et al., 2012). We also
showed that in normal mammary epithelium, TGF-b promotes
mammary stem cells (the presumed cell of origin of Claudinlow
cancers), and it inhibits luminal progenitors (Bruna et al., 2012).
Interestingly, others have shown that in normal breast epithelialorts 13, 2480–2490, December 22, 2015 ª2015 The Authors 2485
A B
Figure 4. Epigenome either Assists or Directs Context-Specific Target Gene Regulation by TGF-b/SMAD3
(A and B) Examples illustrating the epigenome-assisted and epigenome-directed modes for target-gene regulation by TGF-b/SMAD3. ChIP-seq tracks for
MDA-MB-231 are shown in red shades and for HCC-1954 in blue shades. TwoMDA-unique (IGDCC4 and ADAM8) and two HCC-unique (GRAMD2 and IGFBP5)
TGF-b-dependent genes are shown. In the epigenome-assisted mode, differential SMAD3 binding patterns (dashed boxes) are coupled with differential
epigenetic configuration (gray boxes and arrows). In the epigenome-directed mode, SMAD3 binding patterns are the same in both BTICs (dashed boxes), while
epigenetic differences (gray boxes and arrows) are associated with cell-type-specific gene regulation by TGF-b.tissue, LBH promotes stemness and inhibits differentiation (Lind-
ley et al., 2015; Rieger et al., 2010). We therefore sought evi-
dence for a relevant role of LBH in both normal breast epithelium
and in breast cancer. Analysis of gene expression data from
normal human and mouse mammary epithelium revealed that
LBH is highly expressed in the basal (stem cell-containing)
compartment and is downregulated as cells differentiate along
the luminal lineage (Figures 6F, S5C, and S5D). Investigation of
gene expression data from 1,980 primary breast cancers (Curtis
et al., 2012) showed that LBH expression is highest in the Clau-
dinlow subtype (Figure 6D). In patients with Claudinlow tumors,
higher LBH expression correlates with worse survival (Figure 6E).
These findings suggest that the BTIC context-specific TGF-b/
LBH observations we made in model cell lines are relevant to
both normal and malignant primary tissue biology.
DISCUSSION
The mechanisms underlying the opposing TGF-b effects in can-
cer cells, being both pro-oncogenic and tumor suppressive,
remain a significant challenge for inhibition of the pathway as a
feasible cancer therapeutic strategy in the clinic. The current
understanding is that TGF-b stimulation results in different
responses in distinct cell types through the association of
SMAD2/3 with specific SMAD cofactors (Massague´, 2008,2486 Cell Reports 13, 2480–2490, December 22, 2015 ª2015 The Au2012). Accordingly, in normal cells, along a developmental
cascade, SMAD3 co-occupies distinct genomic locations in as-
sociation with cell-type-specific master transcription factors:
Oct4 in embryonic stem cells, Myod1 in myotubes, and PU.1 in
pro-B cells (Mullen et al., 2011). These cofactors are required
for SMAD3 binding, andmost TGF-b-regulated genes are bound
by these master TFs (Mullen et al., 2011). In other words, the
currently accepted model suggests that master TFs are respon-
sible for instructing the gene targets downstream of TGF-b
signaling and thus determine its cell-type-specific effects
(Mullen et al., 2011). In cancer cells, no similar genome-wide
studies have been conducted, but single-gene studies appear
to show analogous findings: TF switches (where SMADs ex-
change binding partners) can occur and result in redirecting of
SMADs from the promoters of tumor suppressor genes to pro-
moters of oncogenes, concomitant with altered transcription of
those target genes (Gomis et al., 2006; Seoane et al., 2004; Xu
et al., 2015).
Our results show for the first time that different SMAD3 binding
patterns cannot fully account for the observed differences in the
TGF-b-dependent transcriptional responses associated with
promotion or suppression of BTICs. In fact, and surprisingly,
the majority of BTIC context-specific TGF-b-dependent genes,
particularly early-responder genes, are bound by SMAD3 in
both contexts. While binding may occur in distinct locationsthors
BA
50
50
40
50
50
40
SMAD3
Pol II
DNA Me
SMAD3
Pol II
DNA Me
LBH
M
D
A
-M
B
-2
31
H
C
C
-1
95
4
32 kb
- + - + - + - +
- +- + - +- +
0
1
2
3
4
5
*
ns
- + - + - + - +
- +- + - +- +
MDA-MB-231 HCC-1954
re
la
tiv
e 
LB
H
 e
xp
re
ss
io
n
re
la
tiv
e 
V
G
LL
3 
ex
pr
es
si
on
TGFβ (24h)
5-aza-dC
TGFβ (24h)
5-aza-dC
MDA-MB-231 HCC-1954
70
50
15
70
50
15
VGLL3
SMAD3
Pol II
DNA Me
SMAD3
Pol II
DNA Me
66 kb
M
D
A
-M
B
-2
31
H
C
C
-1
95
4
DC
LBH VGLL3
0.00
0.05
1
2
3
4
*
*
0.05
Epigenome-directed Epigenome-assisted
*
*
*
*
Figure 5. DNA Methylation Regulates TGF-
b-Dependent Induction of LBH
(A and B) Gene tracks showing SMAD3/Pol II
binding and DNA methylation at LBH and VGLL3
loci. ChIP-seq tracks for MDA-MB-231 are shown in
red shades and for HCC-1954 in blue shades. Also
see Figure S4.
(C and D) qRT-PCRs showing the expression of LBH
and VGLL3 transcripts upon 5-aza-dC and TGF-b
treatments. Cells were treated with 5-aza-dC for
5 days, seeded, and allowed to form mammo-
spheres for 7 days, and then stimulated with TGF-b
for 24 hr. Data were normalized to the housekeeping
(RBM22) transcript levels and are presented as
mean ± SD of three biological replicates. Asterisks
indicate significant differences. ns, not significant
(one-way ANOVA). Also see Figure S4.along the gene, a large fraction of genes possessed coherent
SMAD3 occupancy profiles, many with only identical SMAD3
binding sites. These results reveal that TGF-b-dependent cell-
type-specific transcriptional regulation in cancer cells is not
universally mediated by differential SMAD3 binding. This promp-
ted us to analyze whether additional regulatory mechanisms
operating on chromatin modulate the context-specific target
gene selection by TGF-b/SMAD3.
Very recently, it has been reported that epigenetic configura-
tion of somatic cells predisposes them to reprogramming
fates (Pour et al., 2015). Here we show that tumor initiating cells
harbor distinct epigenetic landscapes that prime specific gene
sets for regulation by TGFb. These distinct epigenetic configu-
rations can act both in synergy with cell-type-specific SMAD3
binding (epigenome-assisted), and independently of cell-type-
specific SMAD3 binding (epigenome-directed), to control TGFb/
SMAD3-dependent context-specific regulation of target genes
(Figure 7).
We propose that epigenome-directed priming in cancer cells
might be a prevalent way of instructing context-specific TGFb ef-
fects. Cancer cells that originate in the same tissue (mammary
epithelium in the case of BTICs), unlike cells from distinct tissue
lineages, are likely to possess similar master TF wiring. But can-
cerswith the same tissueof origin canpossessmarkedly differentCell Reports 13, 2480–2490, Depigenomes, for example, DNA methyl-
ation of gene promoters (Holm et al.,
2010). Here, we reveal an unexpected sim-
ilarity of SMAD3 binding patterns in BTICs
with opposing transcriptional responses
to TGF-b and show that context-specific
TGF-b-dependent genes are frequently
regulated by an epigenome-directed, DNA-
methylation-dependent mechanism, rather
than by differential SMAD3 binding. These
results at the whole-genome level expand
a previous observation in glioma, where
the methylation status of PDGFB predis-
poses tumor cells for either an oncogenic
or a tumor-suppressive response to TGF-b
signaling (Bruna et al., 2007).We have identified LBH, a regulator of epithelial differentiation
in the mammary gland (Lindley et al., 2015; Rieger et al., 2010),
as a mediator required for the context-specific BTIC-promoting
effects of TGF-b, depending on its cell-type-specific methylation
state. The patterns of expression of LBH in normal mammary
development and in human breast cancers are consistent with
its role as a context-specific TGF-b target in primary tissues.
We speculate that many epigenome-directed genes behave
like LBH to mediate the context-specific effects of TGF-b in
cancer.
The model we propose here (Figure 7), that regulation of
transcriptional programs by extracellular growth factors is
dependent on the context-specific epigenomic landscapes of
cancer cells, might not be specific to TGF-b and could have
broader implications for the paracrine effects of the microenvi-
ronment on the malignant compartment of cancers.
EXPERIMENTAL PROCEDURES
Cell Manipulation and Mammosphere Cultures
MDA-MB-231 and HCC-1954 breast cancer cell lines were enriched for
BTICs by mammosphere cultures, as described previously (Bruna et al.,
2012; Dontu et al., 2003a, 2003b). To activate TGF-b signaling, mammo-
spheres were treated with 0.1 nM recombinant TGF-b1. LBH, VGLL3,
SMAD2 and SMAD3 levels were manipulated using siRNA pools (GEecember 22, 2015 ª2015 The Authors 2487
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Figure 6. LBH Is Necessary for TGF-b’s
BTIC-Promoting Activity
(A) MS-IC assay showing the changes in MS-IC
numbers upon TGF-b treatment and siRNA-medi-
ated knockdown of LBH and VGLL3. Mammo-
sphereswere simultaneously treatedwith TGF-b and
siRNA against LBH and VGLL3 for 7 days, second-
generation mammospheres were seeded, and an
MS-IC assay was performed (see Supplemental
Experimental Procedures). Data are presented as
mean ± 95% confidence interval (CI) of nine repli-
cates. Asterisks indicate significant differences. ns,
not significant (one-wayANOVA). Also see Figure S5.
(B) CFC assay showing the effects of TGF-b and
siRNA-mediated knockdown of LBH and VGLL3 on
the proliferation of BTICs.
(C) RRBS analysis of the LBH promoter. x axis
shows eight adjacent CpG sites within the LBH
promoter (highlighted on top); y axis shows binary
methylation calls for each CpG site within 26
sequenced DNA molecules. Genomic track on top
represents the DNA methylation profile of HCC-
1954 BTICs derived by MBD-seq.
(D) Box plots showing the expression of LBH in
different breast cancer subtypes. Significance was
determined by a linear model (ANOVA) and simul-
taneous tests comparing each group to the mean
(see Supplemental Experimental Procedures).
Gene expression data are obtained from the
METABRIC cohort (Curtis et al., 2012).
(E) Survival analysis showing the relationship
between LBH expression and disease-free survival
in the Claudinlow patient group. Patients were
stratified based on top and bottom halves of LBH
expression. Survival function was estimated using
the Kaplan-Meier estimator, and differences be-
tween groups were tested with the log-rank test
(see Supplemental Experimental Procedures).
(F) Expression of LBH in different cell compart-
ments of normal humanmammary epithelium. Basal
compartment, luminal progenitors (LP), and differ-
entiated luminal cells (DL) are shown. Signifi-
cance was determined by a linear model (ANOVA)
comparing LPandDLexpression to thebasal group.
Data from Shehata et al. (2012). Also see Figure S5.Healthcare). To achieve global DNA demethylation, the cells were treated
with 1 mM 5-aza-20-deoxycytidine. For full details, see Supplemental Exper-
imental Procedures.
Chromatin Immunoprecipitation and Sequencing
ChIP-seq was performed using a custom-developed protocol. Briefly, mam-
mospheres (treated with 0.1 nM TGF-b for 3 hr for SMAD3 ChIP-seq, and
untreated in all other experiments) were crosslinked for 45 min with Di(N-suc-
cinimidyl) glutarate (DSG) and 30 min with formaldehyde. Chromatin was ex-
tracted and then sheared using Covaris. Immunoprecipitation was performed
with 10 mg of the corresponding antibodies and protein G agarose beads
(Santa Cruz Biotechnology). Libraries were prepared with TruSeq LT kit (Illu-
mina) and sequenced on HiSeq 2000 (Illumina). For the full protocol, see Sup-
plemental Experimental Procedures.
DNA Methylation Profiling
For MBD-seq, methylated DNA was precipitated with recombinant methyl
binding domain (MBD2b/MBD3L1) protein complex as part of MethylCollec-
tor Ultra kit (Active Motif), following the manufacturer’s recommendations.
Libraries were generated using TruSeq LT kit (Illumina) and sequenced on2488 Cell Reports 13, 2480–2490, December 22, 2015 ª2015 The AuHiSeq 2000 (Illumina). Refer to Supplemental Experimental Procedures for
details.
RRBS was performed as described previously (Boyle et al., 2012).
Targeted bisulfite sequencing was performed using a custom-developed
method (refer to Supplemental Experimental Procedures for details).
ChIP-Seq and MBD-Seq Data Analysis
Sequencing reads were filtered based on quality and aligned to the
Human Genome Build 37 (hg19) using BWA (Li and Durbin, 2009). For
ChIP-seq, SMAD3 peaks were called using MACS (Zhang et al., 2008),
and SICER (Zang et al., 2009) was used for all other factors profiled.
For MBD-seq, bi-asymmetric-Laplace model (BALM) was used to call
methylation peaks (Lan et al., 2011), and (MeD)IP-seq data analysis (MED-
IPS) was used for quantitative analysis, whereby the data were normalized
to the CG content (Lienhard et al., 2014). Downstream analysis of all
datasets was performed in R statistical software (R Development Core
Team, 2009), using edgeR (v3.8.5) for differential binding analysis (Robin-
son et al., 2010) and annovar (2014nov12) for annotation (Wang et al.,
2010). Motif analysis was performed in MEME-ChIP (Machanick and
Bailey, 2011). Tracks representing genomic data were derived from IGVthors
Figure 7. Context-Specific Effects of TGF-b/SMAD3 Are Modulated
by the Epigenome
A model depicting how cell-type-specific epigenetic configurations determine
context-specific effects of TGF-b/SMAD3. Genes differentially bound by
SMAD3 also possess differential levels of open and closed chromatin modi-
fications that will participate in specifying TGF-b-dependent expression of
those genes (epigenome-assisted mechanism). Genes commonly bound by
SMAD3 rely on the underlying cell-type-specific epigenetic configuration for
determining their context-specific regulation by TGF-b (epigenome-directed
mechanism).(Robinson et al., 2011). Refer to Supplemental Experimental Procedures for
details.
Gene Expression Analysis
Gene expression upon TGF-b induction was profiled using Illumina HumanHT-
12 BeadChips. Data were analyzed as previously described (Smyth, 2005).
Refer to Supplemental Experimental Procedures for details.
qRT-PCR
Reverse transcription was performed using Transcriptor First Strand cDNA
Synthesis Kit (Roche), as recommended by the manufacturer. qPCR was
performed using TaqMan Fast Universal PCR Master Mix and gene-specific
TaqMan probes (Applied Biosystems). Refer to Supplemental Experimental
Procedures for details.
Western Blots
The cells were grown asmammospheres for 7 days then treatedwith TGF-b for
1 hr. Total cell lysates were collected, and 20 mg protein was run per condition
on the 10% SDS-PAGE gels. Transfer to nitrocellulose membranes was con-
ducted using semi-dry blotting system (Invitrogen). Membranes were blocked
in 5% dried milk powder, 0.1% Tween-20 in PBS, and the following antibodies
were used for protein detection: rabbit monoclonal against human phospho-
SMAD2 (Ser 465/467) (Cell Signaling, 3108), rabbit polyclonal against human
SMAD2/3 (Santa Cruz Biotechnology, sc-8332) and rabbit polyclonal against
human b-actin (Abcam, ab8227).
Mammosphere-Initiating Cell and Colony-Forming Cell Assays
MS-IC and CFC assays were performed as previously described (Dontu et al.,
2003a, 2003b). Refer to Supplemental Experimental Procedures for details.
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